Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034Martin J. van den Bent, Denis Lacombe, R. Rampling et al.|Journal of Clinical Oncology|2007Cited by 53